Skip to main content

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study

Publication ,  Journal Article
Kinon, BJ; Volavka, J; Stauffer, V; Edwards, SE; Liu-Seifert, H; Chen, L; Adams, DH; Lindenmayer, JP; McEvoy, JP; Buckley, PF; Lieberman, JA ...
Published in: Journal of Clinical Psychopharmacology
2008

The objective of this study was to assess the dose-response relationship of standard and higher doses of olanzapine in a randomized, double-blind, 8-week, fixed-dose study comparing olanzapine 10 (n = 199), 20 (n = 200), and 40 mg/d (n = 200) for patients with schizophrenia or schizoaffective disorder and suboptimal response to current treatment. Patients meeting criteria for antipsychotic treatment resistance were excluded. Dose-response relationship was assessed by linear regression analysis with log-transformed dose (independent variable) and Positive and Negative Syndrome Scale (PANSS) total score (dependent variable). There were no significant dose group differences in patients completing the study (overall, 67.8%). All dose groups showed statistically significant improvement in PANSS total scores from baseline to end point without significant dose-response relationship (P = 0.295). Post hoc analysis of response showed significant interaction between baseline PANSS and dose (P = 0.023), indicating better response at higher doses for patients with higher baseline PANSS. There was a significant dose response for mean change in weight (P = 0.003) with significant difference between the 10- and 40-mg-dose groups (P = 0.002; 1.9 [10 mg/d], 2.3 [20 mg/d], and 3.0 kg [40 mg/d]). There was a significant dose response for change in prolactin (P < 0.001) with a significant difference between each group (-10.5 [10 mg/d], -1.7 [20 mg/d], and 4.9 ng/mL [40 mg/d]; P ≤ 0.018). Over 8 weeks, non-treatment-resistant patients with schizophrenia or schizoaffective disorder responded to all 3 doses of olanzapine, without a statistically significant dose-response relationship, suggesting that for many patients with schizophrenia or schizoaffective disorder, particularly those who are mildly or moderately ill, 10 mg/d should be the initial dose of choice. © 2008 by Lippincott Williams & Wilkins.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Psychopharmacology

DOI

ISSN

0271-0749

Publication Date

2008

Volume

28

Issue

4

Start / End Page

392 / 400

Related Subject Headings

  • Psychiatry
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kinon, B. J., Volavka, J., Stauffer, V., Edwards, S. E., Liu-Seifert, H., Chen, L., … Citrome, L. (2008). Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology, 28(4), 392–400. https://doi.org/10.1097/JCP.0b013e31817e63a5
Kinon, B. J., J. Volavka, V. Stauffer, S. E. Edwards, H. Liu-Seifert, L. Chen, D. H. Adams, et al. “Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study.” Journal of Clinical Psychopharmacology 28, no. 4 (2008): 392–400. https://doi.org/10.1097/JCP.0b013e31817e63a5.
Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology. 2008;28(4):392–400.
Kinon, B. J., et al. “Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study.” Journal of Clinical Psychopharmacology, vol. 28, no. 4, 2008, pp. 392–400. Scival, doi:10.1097/JCP.0b013e31817e63a5.
Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology. 2008;28(4):392–400.

Published In

Journal of Clinical Psychopharmacology

DOI

ISSN

0271-0749

Publication Date

2008

Volume

28

Issue

4

Start / End Page

392 / 400

Related Subject Headings

  • Psychiatry
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences